Skip to content
Peptigraph home
Shop Peptides50% off*

How Kisspeptin-10 Works: Mechanism and Pharmacology

How Kisspeptin-10 works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingGnRH stimulatorUpdated
Class
GnRH stimulator
FDA status
Not approved
research chemical
Routes studied
subcutaneous infusion (kisspeptin-10); intravenous (kisspeptin-10); intravenous and subcutaneous (kisspeptin-10)
Half-life
mean elimination half-life 1.3-2.2 hours
subcutaneous (analog MVT-602), in people · Fertility and sterility 2024, PMID 37925096

How long it acts

Half-life values from FDA labels and published studies, by route. Animal values are labelled and do not describe people.

Kisspeptin-10 half-life by route
RouteHalf-lifeMeasured inSource
subcutaneous (analog MVT-602)mean elimination half-life 1.3-2.2 hoursPeopleFertility and sterility 2024, PMID 37925096
subcutaneous (analog TAK-448)median terminal elimination half-life 1.4-5.3 hoursPeoplePMID 24762108

Full detail, including drug-testing windows, is on the Kisspeptin-10 half-life page.

Receptor and hormone cascade

Kisspeptin acts as the endogenous ligand of the G protein-coupled receptor 54 and regulates the hypothalamic-pituitary-gonadal axis.[3]

In men, kisspeptin-10 raised LH pulse frequency and secretory burst mass during infusion.[4]

In patients with a loss of neurokinin B signalling, continuous kisspeptin infusion restored pulsatile LH secretion.[5]

Why repeated dosing changes the response

In women with hypothalamic amenorrhea, repeated twice-daily injections caused the LH and FSH responses to fall.[6]

Twice-weekly dosing produced only partial desensitization compared with complete tolerance under twice-daily dosing.[7]

In men, the receptor stayed functional after 12 days of intermittent infusion, since a bolus still raised gonadotropins.[8]

Differences by sex and cycle phase

In women the response depends on cycle phase: the LH rise was largest before ovulation and smallest in the follicular phase.[3]

A comparison in healthy men and women found no gonadotropin change in the follicular phase at the maximal doses tested.[9]

Effects outside the reproductive axis

In mice, kisspeptin-10 caused tissue swelling and reduced skin blood flow, indicating vasoactive effects in the small vessels.[10]

In healthy women, kisspeptin-54 did not change growth hormone, prolactin or TSH over 7 days.[11]

Related peptides

Kisspeptin-10 vs PT-141Melanocortin agonistKisspeptin-10 vs EnclomipheneSERM (not a peptide)

Common questions

How long does Kisspeptin-10 act in the body?

The half-life values we found are mean elimination half-life 1.3-2.2 hours (subcutaneous (analog MVT-602)); median terminal elimination half-life 1.4-5.3 hours (subcutaneous (analog TAK-448)). A half-life is how long the amount in the body takes to fall by half; it is not the same as how long an effect lasts.

How does kisspeptin work?

It sits upstream of GnRH: kisspeptin stimulates GnRH neurons, and GnRH drives gonadotropin release.[4]

What is the mechanism of action of kisspeptin?

The receptor target is named, and the cascade runs from kisspeptin through GnRH to LH.[5]

More on Kisspeptin-10

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.BenefitsClaimed benefits next to what published studies measured.

Sources

  1. 1Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
  2. 2Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.The Journal of clinical endocrinology and metabolism · 2014PMID 24762108Accessed 2 Oct 2026
  3. 3Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.The Journal of clinical endocrinology and metabolism · 2007PMID 17635940Accessed 2 Oct 2026
  4. 4Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
  5. 5Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications.Neuroendocrinology · 2013PMID 22377698Accessed 2 Oct 2026
  6. 6Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
  7. 7Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
  8. 8Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
  9. 9The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans.The Journal of clinical endocrinology and metabolism · 2011PMID 21976724Accessed 2 Oct 2026
  10. 10The vasoactive potential of kisspeptin-10 in the peripheral vasculature.PloS one · 2011PMID 21347414Accessed 11 Oct 2026
  11. 11Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women.Clinical endocrinology · 2014PMID 24863252Accessed 2 Oct 2026

Found an error? Report a correction.